---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic impact on families"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic impact on families. Topics: Out-of-pocket costs and financial adjustments reported by U.S. patients and caregivers, Patient and caregiver productivity losses by symptom severity: MyRealWorld MG, Annual productivity losses per patient in the United States by MG-ADL category, Caregiver burden measured with the Zarit Burden Interview in five European countries, and 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Generalized myasthenia gravis on Families

<a id="topic-2.2.1.8.3-1"></a>

### Out-of-pocket costs and financial adjustments reported by U.S. patients and caregivers

> “Eight hundred people with MG and 238 caregivers responding on behalf of a person with MG completed the survey.”
> “70% reported making financial adjustments or seeking financial assistance. Annual out-of-pocket costs (mean, $15,798; median, $7750) were primarily driven by medications, cost to receive a diagnosis, and healthcare insurance premiums. People receiving infusions paid significantly more across all care domains.”

Source: [Yoder et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39697037/)

<a id="topic-2.2.1.8.3-2"></a>

### Patient and caregiver productivity losses by symptom severity: MyRealWorld MG

> “In the MyRealWorld-MG study, 36.5% of MG patients reported taking sick leave within the last month and 11.4% reported stopping work (or retiring early) due to MG. Furthermore, 36.0% required caregiver support with 14.6% of caregivers reducing working hours and 13.4% stopping work.”
> “Patients with severe MG incurred 3.8 times more productivity losses compared to patients with mild disease.”

Source: [Dewilde et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12062151/)

<a id="topic-2.2.1.8.3-3"></a>

### Annual productivity losses per patient in the United States by MG-ADL category

| MG-ADL category | Patient productivity losses | Caregiver productivity losses | Grand total |
| --- | --- | --- | --- |
| Mild | “$8,160” | “$1,302” | “$9,462” |
| Moderate | “$9,063” | “$3,541” | “$12,604” |
| Severe | “$10,997” | “$3,791” | “$14,788” |
| All patients | “$9,468” | “$3,141” | “$12,609” |

Source: [Dewilde et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12062151/)

<a id="topic-2.2.1.8.3-4"></a>

### Caregiver burden measured with the Zarit Burden Interview in five European countries

> “A cross-sectional study design collected patient and caregiver data in Germany, Italy, Spain, the UK, and France.”
> “Caregivers (N = 69) reported a mean ZBI-22 score of 24.3, with 40.6% reporting no burden, 47.8% mild-to-moderate burden, 8.7% moderate-to-severe burden, and 2.9% severe burden.”
> “Informal caregivers of MG patients experience a substantial burden, impacting their physical, emotional, and financial well-being.”

Source: [Dewilde et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12178031/)

<a id="topic-2.2.1.8.3-5"></a>

### Sick leave and need for caregiver help compared with the general population

> “Taking sick leave in the past month was 2.6 times more frequent among people diagnosed with MG compared to the general population (34.4% vs. 13.2%) and four times more people diagnosed with MG reported needing help from a caregiver (34.8% vs. 8.3%).”

Source: [Dewilde et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499690/)

<a id="topic-2.2.1.8.3-6"></a>

### Economic concerns of U.S. adults with gMG facing social determinants of health barriers

> “The survey was completed by 38 individuals living with gMG, the majority of whom were enrolled in public insurance and not employed. The most commonly reported major economic concerns were managing funds for emergency care (66%), loss of income (61%), and non-medical expenses (58%), highlighting the diversity of economic challenges.”

Source: [Hughes et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10520715/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
